Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Releases “Blue Book” Generic Data List
The Ministry of Health, Labor and Welfare (MHLW) on March 31 released the so-called “blue book,” in which data are systematically compiled on the quality of generic drugs for each active pharmaceutical ingredient (API), starting with four APIs (76 products).…
To read the full story
Related Article
- Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
September 14, 2016
REGULATORY
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
- MHLW Insurance Chief Vows Thorough Outreach on OTC-Like Drug Charges
September 3, 2026
- MHLW Scraps Routine Reporting for Type 1 Use under Cartagena Act
September 3, 2026
- Japan to Ease Lifetime Blood Donation Ban for Transfusion Recipients
September 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…